Page 337 - SAMRC AnnualReport 2025-26

F I NAN C IAL I N F O R MA T I O N

ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026
NOTES TO THE ANNUAL FINANCIAL STATEMENTS
(CONTINUED)

31 MARCH 31 MARCH
2026 2025
R R
19. Earmarked funds

Botha trust 151,636 151,636
Bruhns trust 1,760,208 1,656,823
Melville Douglas trust 13,325 13,325
Q&S Abdool Karim trust 3,835,681 3,611,535
FJ Kleynhans trust 111,442 111,442
5,872,292 5,544,761

The Earmarked funds are donations; bequests from deceased estates or cash received for a limited period to be
used for visiting eminent scientists; cancer research or tuberculosis research.

The Earmarked funds are held at the Reserve Bank.
The monies are ring fenced separately from the cash balances of the SAMRC refer to note 8.
The Bruhns and Q & S Abdool Karim trust funds earned interest.

20. Accumulated surplus

Accumulated surplus 581,019,961 473,614,819

The policy of the SAMRC is to maintain a reserve of R50 million to provide for any unforeseen health emergencies.
The accumulated surplus at the end of the reporting period is required to fund capital projects and other
commitments as well as the maintenance of current funding levels of research projects over the MTEF period.
The surplus will also be used to attract equivalent leverage funding from international funders.

21. Revenue

Income from contracts, grants and services rendered (exchange) 437,041,884 546,086,648
Rental income 6,828,433 6,023,856
Gain on exchange differences – 122,888
Fair value adjustments 2,482,462 1,477,299
Other income 24,085,000 20,645,897
Interest received – investment 70,033,419 54,210,410
Dividends received 226,550 182,582
Government grants & subsidies 765,298,611 724,161,231
Income from contracts and grants (non-exchange) 389,220,344 138,597,870
1,695,216,703 1,491,508,681

SA M R C A N N U A L R EP O R T 2 0 2 5 / 2 0 2 6 335